Floatz Rating
D26/100
Confidence
Indicative
Sponsor
NKGen Biotech, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
11Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05099549CT.gov Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| afm24 (this asset) | NKGen Biotech, Inc. | P1/2 | D · 26 |
| Catequentinib | Nanfang Hospital, Southern Medical University | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Durvalumab | OHSU Knight Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Sugemalimab | Second Affiliated Hospital of Soochow University | P2 | BB |
| Nivolumab | CatalYm GmbH | P2 | BB |
| Gm-Csf | Second Affiliated Hospital of Soochow University | P2 | B |
+42 more in the Refractory Malignant Neoplasm cohort
Other indications for afm24
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Squamous Cell Carcinoma | — | P1/2 | D · 26 |
| Colorectal Neoplasm | — | P1/2 | D · 26 |
| Metastatic Neoplasm | — | P1/2 | D · 26 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. afm24 in Refractory Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/afm24-refractory-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →